The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Abstract
Objective To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and venous thrombosis in healthy adult men. Design A nested, case-control study in a prospective cohort. Setting A nationwide study of physicians. Participants The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22,071 male physicians. At entry, 68% of the participants submitted plasma samples that were subsequently frozen at -80 degrees C. During 60.2 months of follow-up, follow-up for nonfatal outcomes was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus. Measurements Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay. The mean anticardiolipin antibody titers of the case patients in the two diagnostic groups (ischemic stroke; venous thrombosis or pulmonary embolus) were compared with those of the control groups, and relative risks were calculated for patients in increasing percentile categories of anticardiolipin antibodies by conditional logistic regression. Results T…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Retrospective, [1][2][3][4] case-control [5][6][7][8][9][10][11][12] and cross-sectional 13,14 studies with different designs, patient selection criteria, aPL profiles and risk factors have produced contradictory results.”
From Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. (2011) · cites this paper as [7]
Citations
Cites
McNeil, H. P., Simpson, R. J., Chesterman, C. N., & Krilis, S. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4120 · Cited by 1,595
Harris, E. N., Boey, M. L., Mackworth-Young, C. G., Gharavi, A. E., Patel, B. M., Loizou, S., & Hughes, G. R. V. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91267-9 · Cited by 1,383
Love, P. E., & Santoro, S. A. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-9-682 · Cited by 1,095
The “Primary” Antiphospholipid Syndrome
Asherson, R. A., Khamashta, M. A., Ordi, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · Medicine · doi:10.1097/00005792-198911000-00004 · Cited by 963
The "primary" antiphospholipid syndrome: major clinical and serological features.
Asherson, R. A., Khamashta, M. A., Ordi‐Ros, J., Derksen, R. H. W. M., Machin, S. J., Barquinero, J., OUTT, H. H., Harris, E. N., Vilardell, M., & Hughes, G. R. V. (1989) · PubMed · Cited by 892
Alarcón-Segovia, D., Delezé, M., Oria, C. V., Sánchez‐Guerrero, J., Gómez-Pacheco, L., Cabiedes, J., Fernández, L. A. N., & de León, S. P. (1989) · Medicine · doi:10.1097/00005792-198911000-00003 · Cited by 635
Carreras, L., Machin, S. J., Deman, R., DEFREYN, G., Vermylen, J., Spitz, B., & Assche, A. V. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92087-0 · Cited by 551
Loizou, S., McCrea, J. D., Rudge, A. C., Reynolds, R., Boyle, C. C., & Harris, E. N. (1985) · PubMed Central · Cited by 549
Thrombosis, Recurrent Fetal Loss, and Thrombocytopenia
Harris, E. N. (1986) · Archives of Internal Medicine · doi:10.1001/archinte.1986.00360230069012 · Cited by 546
Preliminary Report: Findings from the Aspirin Component of the Ongoing Physicians' Health Study
The Steering Committee of the Physicians' Health Study Research Group (1988) · New England Journal of Medicine · doi:10.1056/nejm198801283180431 · Cited by 522
Research works printed but not linked: 15
- Meyer O, 1987, J Rheum., 14, 502
- Colaco C, 1983, Ann Rheum Dis., 42, 228
- Harris E, 1985, J Clin Lab Immunol., 16, 1
- Colaco C, 1985, Clin Exp Immunol., 59, 449
- Harris E, 1987, Clin Exp Immunol., 68, 215
- Hall S, 1984, J Rheum., 11, 846
- Asherson R, 1989, Q J Med., 73, 1103
- Cronin M, 1988, J Rheum., 15, 795
- Klemp P, 1988, Clin Exp Immunol., 74, 254
- Lavalle C, 1990, J Rheum., 17, 34
- Coon W, 1976, Surg Gynecol Obstet., 143, 385
- Hasselaar P, 1990, J Rheumatol., 17, 186
- Loizou S, 1985, Clin Exp Immunol., 62, 738
- Ruiz-Arguelles G, 1989, J Rheumatol., 16, 381
- McNeil H, 1990, Clin Exp Rheumatol., 8, 525
Cited by
Sorted by citations
Items 501–525 of 525
Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome
Amengual, O., Bertolaccini, M. L., & Atsumi, T. (2016) · Technical report · doi:10.1016/b978-0-444-63655-3.00004-1
Coronary Artery Disease in Systemic Lupus Erythematosus
Nilsson, J. Å. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.08.016
Treatment of “Other” Stroke Etiologies
Kasner, S. E., & Cucchiara, B. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29544-4.00056-6
Erkan, D., & Lockshin, M. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00074-x
Manifestaciones cutáneas del síndrome antifosfolípido
Martínez, R. C., Merino, L. T., Mera, C. M., & Gullón, G. R. (2020) · Piel · doi:10.1016/j.piel.2019.12.015
Incidence of Deep Vein Thrombosis in the Lower Extremity
de Wet, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Treatment of Antiphospholipid Syndrome
Sciascia, S., & Khamashta, M. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801917-7.00063-2
Antiphospholipid Syndrome – Early Pregnancy Loss
Thakur, N. (2021) · Asian Journal of Nursing Education and Research · doi:10.52711/2349-2996.2021.00136
Al-Osaimi, H., & Althubiti, A. (2021) · Springer eBooks · doi:10.1007/978-981-15-8323-0_17
Stankić, D., & Miljić, P. (2022) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk3-32463
Treatment of antiphospholipid syndrome
Sciascia, S., & Khamashta, M. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00065-9
Antigenic specificities of “antiphospholipid” autoantibodies
Roubey, R. A. S. (1995) · Springer eBooks · doi:10.1007/978-3-642-79622-7_6
Lupus Anticoagulants: Mechanistic and Diagnostic Considerations
Arnout, J., & Vermylen, J. (2000) · Springer eBooks · doi:10.1007/978-1-4471-3666-8_23
Task Force Report on “Criteria” Antiphospholipid Antibody Tests
Roubey, R. A. S., & Pierangeli, S. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3194-7_7
Jansen, J., Johnsen, B., & Johansen, S. (1988) · PubMed
Smith, J. B., & Cowchock, F. S. (1994) · Immunology and Allergy Clinics of North America · doi:10.1016/s0889-8561(22)00345-9
A rare presentation of primary apla and pulmonary thrombolism
Chinnasamy, V., Kumar, K., & Gnanadeepan, T. (2023) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20230370
Is a Higher Body Mass Index a Risk Factor for Developing Antiphospholipid Antibody Syndrome?
Mansory, E. M., Badawi, A., Rajab, R., Abdullah, A., Alhiniah, M. H., Alelyani, R. H., Al-Mughales, J., Alahwal, H. M., & Barefah, A. S. (2023) · Cureus · doi:10.7759/cureus.42982
Cardiolipin Antibodies in Biopsy-defined Adult Celiac Disease
Freeman, H. J. (2024) · Acta Scientific Medical Sciences · doi:10.31080/asms.2024.08.1775
Accelerated Atherogenesis and Antiphospholipid Antibodies
Matsuura, E., Kobayashi, K., & Lopez, L. R. (2006) · Springer eBooks · doi:10.1007/1-84628-009-5_40
Autoantibodies to Endothelial Cells and Oxidized LDL in Human Atherosclerosis and Hypertension
Frostegrd, J. (2001) · Elsevier eBooks · doi:10.1016/b978-044450669-6/50017-7
Atherogenesis and atherosclerosis in primary antiphospholipid syndrome
Ames, P. R. J. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Ren, X. S., Kazis, L., & Meenan, R. F. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)12:3
Metadata
- Authors
- Ginsburg, K. S., Liang, M. H., Newcomer, L., Goldhaber, S. Z., Schur, P. H., Hennekens, C. H., & Stampfer, M. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 1992-12-15
- Volume
- 117
- Issue
- 12
- Pages
- 997-1002
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1491481195
- Cited by
- 526
- References
- 49
- Citations by year
- 2025: 2 · 2024: 7 · 2023: 5 · 2022: 1 · 2021: 8 · 2020: 8 · 2019: 4 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 10 · 2013: 15 · 2012: 16
- FWCI
- 16.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA042182, CA 42182)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P60AR036308, AR-36308, AR-07530, T32AR007530)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- anticardiolipin antibodies, ischemic stroke, venous thrombosis, deep vein thrombosis, pulmonary embolism, thrombophilia, risk factors, IgG, male physicians, Physicians' Health Study, aspirin, beta-carotene, anticoagulation, stroke prevention, antithrombotic therapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Brain Ischemia, Enzyme-Linked Immunosorbent Assay, Humans, Male, Middle Aged, Prospective Studies, Pulmonary Embolism, Risk Factors, Statistics as Topic, Thrombophlebitis, Case-Control Studies, Antibodies, Anticardiolipin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review